Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

521235 PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem

The PDGFR Tyrosine Kinase Inhibitor VI, SU6668, also referenced under CAS 210644-62-5, controls the biological activity of PDGFR Tyrosine Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: (Z)-3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid, Aurora Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XXVII, VEGFR2 Kinase Inhibitor XXV, mTOR Inhibitor X

521235
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
210644-62-5C₁₈H₁₈N₂O₃
Description
Overview

This product has been discontinued.



A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively).
Catalogue Number521235
Brand Family Calbiochem®
Synonyms(Z)-3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid, Aurora Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XXVII, VEGFR2 Kinase Inhibitor XXV, mTOR Inhibitor X
References
ReferencesGodl, K., et al. 2005. Cancer Res. 65, 6919.
Laird, A.D., et al. 2002. FASEB J. 16, 681.
Krystal, G.W., et al. 2001. Cancer Res. 61, 3660.
Smolich, B.D., et al. 2001. Blood 97, 1413.
Laird, A.D., et al. 2000. Cancer Res. 60, 4152.
Shaheen, R.M., et al. 1999. Cancer Res. 59, 5412.
Sun, L. et al. 1999. J. Med. Chem. 42, 5120.
Product Information
CAS number210644-62-5
FormDark yellow solid
Hill FormulaC₁₈H₁₈N₂O₃
Chemical formulaC₁₈H₁₈N₂O₃
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥97% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
R PhraseR: 22-36/37/38

Harmful if swallowed.
Irritating to eyes, respiratory system and skin.
S PhraseS: 26-36-45

In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Wear suitable protective clothing.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
521235 0

Documentation

PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem Certificates of Analysis

TitleLot Number
521235

References

Reference overview
Godl, K., et al. 2005. Cancer Res. 65, 6919.
Laird, A.D., et al. 2002. FASEB J. 16, 681.
Krystal, G.W., et al. 2001. Cancer Res. 61, 3660.
Smolich, B.D., et al. 2001. Blood 97, 1413.
Laird, A.D., et al. 2000. Cancer Res. 60, 4152.
Shaheen, R.M., et al. 1999. Cancer Res. 59, 5412.
Sun, L. et al. 1999. J. Med. Chem. 42, 5120.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision06-April-2009 RFH
Synonyms(Z)-3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid, Aurora Kinase Inhibitor IV, VEGFR Tyrosine Kinase Inhibitor XXVII, VEGFR2 Kinase Inhibitor XXV, mTOR Inhibitor X
DescriptionA cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 µM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 µM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 µM, respectively).
FormDark yellow solid
Intert gas (Yes/No) Packaged under inert gas
CAS number210644-62-5
Chemical formulaC₁₈H₁₈N₂O₃
Structure formulaStructure formula
Purity≥97% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Harmful
ReferencesGodl, K., et al. 2005. Cancer Res. 65, 6919.
Laird, A.D., et al. 2002. FASEB J. 16, 681.
Krystal, G.W., et al. 2001. Cancer Res. 61, 3660.
Smolich, B.D., et al. 2001. Blood 97, 1413.
Laird, A.D., et al. 2000. Cancer Res. 60, 4152.
Shaheen, R.M., et al. 1999. Cancer Res. 59, 5412.
Sun, L. et al. 1999. J. Med. Chem. 42, 5120.